BRAFMutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
- Resource Type
- Article
- Authors
- Dudnik, Elizabeth; Peled, Nir; Nechushtan, Hovav; Wollner, Mira; Onn, Amir; Agbarya, Abed; Moskovitz, Mor; Keren, Shoshana; Popovits-Hadari, Noa; Urban, Damien; Mishaeli, Moshe; Zer, Alona; Allen, Aaron M.; Rabinovich, Natalie Maimon; Rotem, Ofer; Kuznetsov, Teodor; Shochat, Tzippy; Roisman, Laila C.; Bar, Jair
- Source
- Journal of Thoracic Oncology; August 2018, Vol. 13 Issue: 8 p1128-1137, 10p
- Subject
- Language
- ISSN
- 15560864; 15561380
The efficacy of immune checkpoint inhibitors (ICPi) in BRAFmutant NSCLC is unknown.